Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Emily Pei-Ying Lin
Observed names:
E.P. Lin,
Emily Pei-Ying. Lin
Institutions:
Taipei Medical University Hospital,
Taipei Medical University
Observed institutions:
Fu Jen Catholic University,
Taipei Medical University Hospital,
Institute of Biomedical Sciences, Academia Sinica,
National Taiwan University Hospital,
Taipei Medical University,
Academia Sinica,
Vanderbilt University Medical Center
show all 7
ORCID:
0000-0002-1178-0597
Observed ORCID:
0000-0002-1178-0597
OpenAlex ID:
A5023487139
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy
2020
·
Satya Das
, Kristen K. Ciombor
, et al.
·
The Oncologist
·
44
Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment: A Systematic Review and Meta-analyses
2022
·
Emily Pei-Ying Lin
, Chih-Yuan Hsu
, et al.
·
JAMA Network Open
·
35
PDF
Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy.
2019
·
Satya Das
, Kristen Keon Ciombor
, et al.
·
Journal of Clinical Oncology
·
15
AptBCis1, An Aptamer–Cisplatin Conjugate, Is Effective in Lung Cancer Leptomeningeal Carcinomatosis
2024
·
Bo-Tsang Huang
, Wei-Yun Lai
, et al.
·
ACS Nano
·
14
Priming PD-L1 expression by chemotherapeutic agents in non-small cell lung cancers.
2017
·
Emily Pei-Ying Lin
, Ching-Yao Yang
, et al.
·
Journal of Clinical Oncology
·
13
Cox Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors: Cox-TEL Adjustment and Meta-Analyses of Programmed Death-Ligand 1 Expression and Immune Checkpoint Inhibitor Survival Benefit
2022
·
Emily Pei-Ying Lin
, Chih-Yuan Hsu
, et al.
·
Journal of Thoracic Oncology
·
4
PINK1-Mediated Inhibition of EGFR Dimerization and Activation Impedes EGFR-Driven Lung Tumorigenesis
2021
·
Emily Pei-Ying Lin
, Bo-Tsang Huang
, et al.
·
Cancer Research
·
4
PDF
Associations of COVID-19 vaccination with risks for post-infectious cardiovascular complications: an international cohort study in cancer patients with SARS-CoV-2 infection
2025
·
Emily Pei-Ying Lin
, Chih-Yuan Hsu
, et al.
·
The Lancet Regional Health - Americas
·
3
Changing paradigm in oncology clinical trials: Cox-TEL—Adjustment made ready for early crossover and tail tale.
2020
·
Emily Pei-Ying Lin
, Chih-Yuan Hsu
, et al.
·
Journal of Clinical Oncology
·
3
Associations of influenza vaccination with severity of immune-related adverse events in patients with advanced thoracic cancers on immune checkpoint inhibitors
2022
·
Emily Pei-Ying Lin
, Li-Ching Huang
, et al.
·
ERJ Open Research
·
2
PDF
Abstract A019: Targeted CNS Oncology Using Multispecific DNA-Based Therapeutics
2026
·
Emily Pei-Ying. Lin
, Bo-Tsang Huang
·
Clinical Cancer Research
Abstract 1305: Assisted reproductive technology and the risk of female sex hormone-related cancers.
2026
·
Emily Pei-Ying Lin
, Ching-Heng Lin
, et al.
·
Cancer Research
Abstract 2379: AptBCis2 plus pemetrexed for lung cancer leptomeningeal carcinomatosis and cancer-associated cachexia
2025
·
Emily Pei-Ying Lin
, Bo-Tsang Huang
·
Cancer Research
Data from PINK1-Mediated Inhibition of EGFR Dimerization and Activation Impedes EGFR-Driven Lung Tumorigenesis
2023
·
Emily Pei-Ying Lin
, Bo-Tsang Huang
, et al.
Supplementary Data from PINK1-Mediated Inhibition of EGFR Dimerization and Activation Impedes EGFR-Driven Lung Tumorigenesis
2023
·
Emily Pei-Ying Lin
, Bo-Tsang Huang
, et al.
Data from PINK1-Mediated Inhibition of EGFR Dimerization and Activation Impedes EGFR-Driven Lung Tumorigenesis
2023
·
Emily Pei-Ying Lin
, Bo-Tsang Huang
, et al.
P2.04-50 Advanced Statistical Approach Tells the Difference: Taylor-Expansion Adjustment for Survival Analyses in Immunotherapy Trials
2019
·
C. Hsu
, E.P. Lin
, et al.
·
Journal of Thoracic Oncology
PDF
Show more works
View as search
Works count:
17
Citation count:
137
H-index:
5
I10-index:
5
Year
Topic
Type